Michele Annette Gadd, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mastectomy, Segmental | 29 | 2024 | 961 | 2.080 |
Why?
|
Breast Neoplasms | 90 | 2024 | 21162 | 1.900 |
Why?
|
Mastectomy | 26 | 2024 | 1851 | 1.880 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 17 | 2024 | 936 | 1.160 |
Why?
|
Nipples | 11 | 2024 | 230 | 1.110 |
Why?
|
Carcinoma, Ductal, Breast | 18 | 2024 | 1094 | 1.100 |
Why?
|
Sentinel Lymph Node Biopsy | 14 | 2024 | 740 | 0.980 |
Why?
|
Neoplasm, Residual | 7 | 2024 | 1019 | 0.810 |
Why?
|
Mammaplasty | 11 | 2023 | 1263 | 0.730 |
Why?
|
Carcinoma, Lobular | 12 | 2020 | 480 | 0.700 |
Why?
|
Neoplasm Recurrence, Local | 22 | 2024 | 9433 | 0.650 |
Why?
|
Carcinoma in Situ | 5 | 2019 | 789 | 0.630 |
Why?
|
Intraoperative Care | 4 | 2023 | 771 | 0.600 |
Why?
|
Mastectomy, Subcutaneous | 6 | 2024 | 56 | 0.590 |
Why?
|
Peptide Hydrolases | 2 | 2021 | 610 | 0.590 |
Why?
|
Neoplasm Staging | 25 | 2024 | 11254 | 0.480 |
Why?
|
Mammography | 14 | 2019 | 2434 | 0.470 |
Why?
|
Axilla | 10 | 2024 | 628 | 0.470 |
Why?
|
Breast | 11 | 2020 | 1975 | 0.440 |
Why?
|
Breast Implantation | 3 | 2020 | 224 | 0.420 |
Why?
|
Lymph Node Excision | 13 | 2020 | 1274 | 0.400 |
Why?
|
Lymphatic Metastasis | 19 | 2024 | 2925 | 0.350 |
Why?
|
Female | 107 | 2024 | 397089 | 0.240 |
Why?
|
Surgery, Computer-Assisted | 3 | 2023 | 1006 | 0.240 |
Why?
|
Follow-Up Studies | 31 | 2024 | 39407 | 0.240 |
Why?
|
Emigration and Immigration | 2 | 2005 | 406 | 0.240 |
Why?
|
Risk Assessment | 8 | 2020 | 24318 | 0.210 |
Why?
|
Middle Aged | 78 | 2024 | 223491 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
Mammary Glands, Human | 2 | 2014 | 202 | 0.200 |
Why?
|
Radiotherapy, Conformal | 3 | 2014 | 549 | 0.190 |
Why?
|
Retrospective Studies | 47 | 2023 | 81801 | 0.190 |
Why?
|
Neoplasm Invasiveness | 7 | 2024 | 3633 | 0.190 |
Why?
|
Lymph Nodes | 9 | 2020 | 3471 | 0.190 |
Why?
|
Adult | 71 | 2024 | 223640 | 0.190 |
Why?
|
Cyclin D1 | 3 | 2001 | 453 | 0.180 |
Why?
|
X-Ray Microtomography | 2 | 2013 | 457 | 0.180 |
Why?
|
Prognosis | 18 | 2024 | 30022 | 0.170 |
Why?
|
Pandemics | 1 | 2020 | 8753 | 0.170 |
Why?
|
Mammary Glands, Animal | 1 | 2001 | 273 | 0.170 |
Why?
|
Ataxia Telangiectasia | 1 | 2021 | 107 | 0.170 |
Why?
|
Aged | 57 | 2024 | 171562 | 0.170 |
Why?
|
Humans | 109 | 2024 | 768393 | 0.170 |
Why?
|
Convalescence | 1 | 2020 | 109 | 0.170 |
Why?
|
Melanoma | 10 | 2004 | 5705 | 0.170 |
Why?
|
Radio Frequency Identification Device | 1 | 2019 | 24 | 0.160 |
Why?
|
Postoperative Complications | 6 | 2020 | 15881 | 0.160 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2001 | 710 | 0.150 |
Why?
|
Patient Selection | 4 | 2020 | 4266 | 0.150 |
Why?
|
Brachytherapy | 3 | 2012 | 1226 | 0.150 |
Why?
|
Cathepsins | 1 | 2018 | 241 | 0.140 |
Why?
|
Physical Exertion | 1 | 2020 | 669 | 0.140 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2021 | 555 | 0.140 |
Why?
|
Radiodermatitis | 2 | 2014 | 61 | 0.130 |
Why?
|
Surgical Flaps | 3 | 2020 | 1682 | 0.120 |
Why?
|
Diagnostic Imaging | 2 | 2020 | 3541 | 0.120 |
Why?
|
Aged, 80 and over | 27 | 2024 | 59686 | 0.120 |
Why?
|
Biopsy | 10 | 2022 | 6808 | 0.120 |
Why?
|
Photons | 3 | 2014 | 595 | 0.120 |
Why?
|
Skin Neoplasms | 9 | 2004 | 5857 | 0.120 |
Why?
|
Reoperation | 6 | 2021 | 4341 | 0.120 |
Why?
|
Neoplasms, Second Primary | 2 | 2021 | 1060 | 0.120 |
Why?
|
Analgesics, Opioid | 2 | 2022 | 3836 | 0.120 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2021 | 1794 | 0.110 |
Why?
|
Precancerous Conditions | 3 | 2017 | 984 | 0.110 |
Why?
|
Survival Rate | 12 | 2024 | 12870 | 0.110 |
Why?
|
Keratin-19 | 1 | 2013 | 33 | 0.110 |
Why?
|
Receptors, Estrogen | 4 | 2016 | 2247 | 0.100 |
Why?
|
Feasibility Studies | 3 | 2020 | 5313 | 0.100 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1885 | 0.100 |
Why?
|
Neoadjuvant Therapy | 3 | 2020 | 2909 | 0.100 |
Why?
|
Fluorescent Dyes | 1 | 2020 | 1926 | 0.100 |
Why?
|
Data Mining | 1 | 2016 | 560 | 0.100 |
Why?
|
Sweden | 2 | 2005 | 1383 | 0.090 |
Why?
|
Anticarcinogenic Agents | 1 | 2012 | 251 | 0.090 |
Why?
|
Lymphedema | 2 | 2012 | 527 | 0.090 |
Why?
|
Treatment Outcome | 21 | 2020 | 65379 | 0.090 |
Why?
|
Chemoprevention | 1 | 2012 | 326 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2016 | 1536 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2016 | 3553 | 0.080 |
Why?
|
Prospective Studies | 15 | 2024 | 54920 | 0.080 |
Why?
|
Pectoralis Muscles | 2 | 2020 | 86 | 0.080 |
Why?
|
Costs and Cost Analysis | 2 | 2012 | 1669 | 0.080 |
Why?
|
Pain, Postoperative | 1 | 2019 | 1765 | 0.080 |
Why?
|
Radiotherapy Dosage | 5 | 2021 | 2922 | 0.080 |
Why?
|
Genes, BRCA2 | 3 | 2008 | 592 | 0.080 |
Why?
|
Incidence | 8 | 2019 | 21544 | 0.080 |
Why?
|
Cardiovascular Diseases | 2 | 2005 | 15649 | 0.080 |
Why?
|
Extremities | 1 | 1993 | 870 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 1076 | 0.070 |
Why?
|
Genes, BRCA1 | 3 | 2008 | 755 | 0.070 |
Why?
|
Carcinoma, Ductal | 1 | 2008 | 97 | 0.070 |
Why?
|
Hyperplasia | 3 | 2017 | 1153 | 0.070 |
Why?
|
BRCA2 Protein | 2 | 2023 | 802 | 0.070 |
Why?
|
Combined Modality Therapy | 7 | 2019 | 8562 | 0.070 |
Why?
|
Monitoring, Intraoperative | 1 | 2013 | 950 | 0.070 |
Why?
|
Pneumonectomy | 1 | 1993 | 1158 | 0.070 |
Why?
|
Tumor Burden | 3 | 2019 | 1913 | 0.070 |
Why?
|
Nomograms | 1 | 2008 | 236 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 957 | 0.070 |
Why?
|
Risk Factors | 15 | 2020 | 74962 | 0.070 |
Why?
|
Self Disclosure | 1 | 2007 | 249 | 0.070 |
Why?
|
Interferon-alpha | 2 | 2000 | 910 | 0.060 |
Why?
|
BRCA1 Protein | 2 | 2023 | 1155 | 0.060 |
Why?
|
Intraoperative Period | 2 | 2018 | 513 | 0.060 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 3 | 1999 | 63 | 0.060 |
Why?
|
Soft Tissue Neoplasms | 1 | 1993 | 1167 | 0.060 |
Why?
|
Patient Satisfaction | 6 | 2021 | 3486 | 0.060 |
Why?
|
Thoracic Vertebrae | 1 | 2008 | 613 | 0.060 |
Why?
|
SEER Program | 2 | 2019 | 1474 | 0.060 |
Why?
|
Cyclins | 2 | 1997 | 606 | 0.060 |
Why?
|
Poisson Distribution | 1 | 2005 | 509 | 0.050 |
Why?
|
Age Factors | 6 | 2021 | 18471 | 0.050 |
Why?
|
Medical History Taking | 1 | 2007 | 776 | 0.050 |
Why?
|
Fat Necrosis | 2 | 2014 | 60 | 0.050 |
Why?
|
Research Subjects | 1 | 2005 | 249 | 0.050 |
Why?
|
Age Distribution | 3 | 2005 | 2877 | 0.050 |
Why?
|
Sarcoma | 1 | 1993 | 1807 | 0.050 |
Why?
|
Mammary Tumor Virus, Mouse | 1 | 2001 | 41 | 0.050 |
Why?
|
Spinal Neoplasms | 1 | 2008 | 716 | 0.050 |
Why?
|
Oncogene Proteins | 2 | 1997 | 718 | 0.050 |
Why?
|
Breast Implants | 2 | 2019 | 414 | 0.050 |
Why?
|
Postoperative Period | 2 | 2020 | 1830 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 4 | 2017 | 36849 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2016 | 20224 | 0.050 |
Why?
|
Genetic Testing | 3 | 2009 | 3587 | 0.050 |
Why?
|
Telangiectasis | 2 | 2014 | 78 | 0.040 |
Why?
|
Coloring Agents | 3 | 2016 | 564 | 0.040 |
Why?
|
Young Adult | 9 | 2021 | 60049 | 0.040 |
Why?
|
Skin | 1 | 2014 | 4499 | 0.040 |
Why?
|
3T3 Cells | 1 | 2001 | 1086 | 0.040 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2000 | 140 | 0.040 |
Why?
|
Time Factors | 9 | 2020 | 40272 | 0.040 |
Why?
|
Radiation Injuries | 2 | 2021 | 1204 | 0.040 |
Why?
|
Calcinosis | 1 | 2008 | 1481 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2012 | 5538 | 0.040 |
Why?
|
Lactation | 1 | 2001 | 397 | 0.040 |
Why?
|
Regression Analysis | 2 | 2011 | 6350 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2016 | 4875 | 0.040 |
Why?
|
Disclosure | 1 | 2005 | 754 | 0.040 |
Why?
|
Health Care Costs | 1 | 2012 | 3267 | 0.040 |
Why?
|
Phyllodes Tumor | 1 | 1999 | 54 | 0.040 |
Why?
|
Acetates | 1 | 2000 | 317 | 0.040 |
Why?
|
Amines | 1 | 2000 | 280 | 0.040 |
Why?
|
Premenopause | 2 | 2016 | 1039 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2019 | 160 | 0.040 |
Why?
|
Stereotaxic Techniques | 1 | 2001 | 556 | 0.040 |
Why?
|
Sex Distribution | 1 | 2003 | 2281 | 0.040 |
Why?
|
Geographic Information Systems | 1 | 2020 | 283 | 0.040 |
Why?
|
Immunohistochemistry | 4 | 2018 | 11120 | 0.040 |
Why?
|
Data Collection | 1 | 2007 | 3324 | 0.040 |
Why?
|
Anti-Anxiety Agents | 1 | 2000 | 405 | 0.040 |
Why?
|
Radionuclide Imaging | 4 | 2008 | 1998 | 0.040 |
Why?
|
Esthetics | 2 | 2011 | 330 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 4 | 2008 | 18048 | 0.040 |
Why?
|
Surgical Mesh | 1 | 2020 | 316 | 0.030 |
Why?
|
Peptide Initiation Factors | 1 | 1996 | 53 | 0.030 |
Why?
|
Perceptual Distortion | 1 | 1996 | 36 | 0.030 |
Why?
|
Antimanic Agents | 1 | 2000 | 524 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2001 | 6132 | 0.030 |
Why?
|
Disease-Free Survival | 4 | 2016 | 6856 | 0.030 |
Why?
|
Pilot Projects | 3 | 2020 | 8731 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2020 | 1585 | 0.030 |
Why?
|
Neoplasms | 2 | 2020 | 22385 | 0.030 |
Why?
|
Survival Analysis | 3 | 2017 | 10117 | 0.030 |
Why?
|
Preoperative Care | 2 | 2019 | 2258 | 0.030 |
Why?
|
General Surgery | 2 | 1997 | 1713 | 0.030 |
Why?
|
Antineoplastic Agents | 3 | 2005 | 13697 | 0.030 |
Why?
|
Organ Specificity | 1 | 2020 | 1967 | 0.030 |
Why?
|
Perimenopause | 1 | 2016 | 142 | 0.030 |
Why?
|
Registries | 3 | 2007 | 8379 | 0.030 |
Why?
|
Carcinoma, Merkel Cell | 1 | 1999 | 330 | 0.030 |
Why?
|
Device Removal | 1 | 2020 | 643 | 0.030 |
Why?
|
Tamoxifen | 2 | 2012 | 968 | 0.030 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1996 | 781 | 0.030 |
Why?
|
Cell Division | 1 | 2001 | 4479 | 0.030 |
Why?
|
Heterozygote | 1 | 2021 | 2791 | 0.030 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2000 | 1143 | 0.030 |
Why?
|
Treatment Failure | 2 | 2013 | 2663 | 0.030 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 15455 | 0.030 |
Why?
|
Foot | 1 | 1997 | 577 | 0.030 |
Why?
|
Groin | 1 | 1992 | 106 | 0.030 |
Why?
|
Postmenopause | 2 | 2016 | 2518 | 0.030 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 100 | 0.030 |
Why?
|
Male | 16 | 2020 | 364902 | 0.020 |
Why?
|
Ovarian Neoplasms | 2 | 2007 | 4907 | 0.020 |
Why?
|
Skin Pigmentation | 1 | 2014 | 278 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2001 | 3413 | 0.020 |
Why?
|
Radiopharmaceuticals | 2 | 1999 | 2734 | 0.020 |
Why?
|
Mutation | 4 | 2023 | 30228 | 0.020 |
Why?
|
Hand | 1 | 1997 | 912 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2021 | 2593 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 2013 | 313 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2005 | 8051 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 1996 | 998 | 0.020 |
Why?
|
Androstadienes | 1 | 2012 | 348 | 0.020 |
Why?
|
Preventive Medicine | 1 | 2012 | 246 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2001 | 3612 | 0.020 |
Why?
|
Cyanoacrylates | 1 | 2010 | 47 | 0.020 |
Why?
|
Head and Neck Neoplasms | 3 | 2001 | 2923 | 0.020 |
Why?
|
Neoplasm Metastasis | 2 | 2016 | 4921 | 0.020 |
Why?
|
Photography | 1 | 2013 | 537 | 0.020 |
Why?
|
Skin, Artificial | 1 | 2010 | 89 | 0.020 |
Why?
|
Lymphatic Irradiation | 1 | 2010 | 115 | 0.020 |
Why?
|
Receptors, Progesterone | 2 | 2010 | 1145 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2990 | 0.020 |
Why?
|
Arm | 1 | 2012 | 590 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2001 | 9562 | 0.020 |
Why?
|
Tissue Expansion | 1 | 2010 | 163 | 0.020 |
Why?
|
Age of Onset | 1 | 2016 | 3345 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2012 | 12092 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 1993 | 13576 | 0.020 |
Why?
|
Tissue Adhesives | 1 | 2010 | 179 | 0.020 |
Why?
|
Bandages | 1 | 2010 | 273 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2537 | 0.020 |
Why?
|
Pregnancy | 2 | 2019 | 30200 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2005 | 14784 | 0.020 |
Why?
|
Early Detection of Cancer | 2 | 2015 | 3236 | 0.020 |
Why?
|
False Negative Reactions | 2 | 1999 | 575 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2005 | 6406 | 0.020 |
Why?
|
Research | 1 | 1996 | 1981 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 7453 | 0.020 |
Why?
|
Microcomputers | 1 | 2007 | 139 | 0.020 |
Why?
|
Cohort Studies | 3 | 2014 | 41795 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6541 | 0.020 |
Why?
|
Internship and Residency | 2 | 1997 | 5949 | 0.020 |
Why?
|
Receptor, erbB-2 | 2 | 2010 | 2588 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1555 | 0.020 |
Why?
|
Length of Stay | 1 | 2019 | 6519 | 0.020 |
Why?
|
Decision Making | 1 | 2019 | 3953 | 0.020 |
Why?
|
Recurrence | 2 | 2001 | 8506 | 0.020 |
Why?
|
Sensitivity and Specificity | 3 | 2007 | 14737 | 0.020 |
Why?
|
Matched-Pair Analysis | 1 | 2005 | 286 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 1996 | 5801 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2008 | 594 | 0.010 |
Why?
|
Electrons | 1 | 2006 | 264 | 0.010 |
Why?
|
Fibrosis | 1 | 2011 | 2077 | 0.010 |
Why?
|
Cicatrix | 1 | 2010 | 799 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2001 | 11668 | 0.010 |
Why?
|
Iridium Radioisotopes | 1 | 2003 | 26 | 0.010 |
Why?
|
Carcinoma | 1 | 1995 | 2341 | 0.010 |
Why?
|
Bipolar Disorder | 1 | 2000 | 5126 | 0.010 |
Why?
|
Exercise | 1 | 2020 | 5946 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1397 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 1996 | 3922 | 0.010 |
Why?
|
Collagen | 1 | 2010 | 2646 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6993 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 11854 | 0.010 |
Why?
|
Radiotherapy | 1 | 2008 | 1509 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6241 | 0.010 |
Why?
|
Adolescent | 5 | 2001 | 89184 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 8075 | 0.010 |
Why?
|
Aromatase Inhibitors | 1 | 2005 | 519 | 0.010 |
Why?
|
Technetium | 1 | 2001 | 326 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2006 | 2862 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 2000 | 6510 | 0.010 |
Why?
|
ROC Curve | 1 | 2008 | 3623 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 3438 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1280 | 0.010 |
Why?
|
Primary Prevention | 1 | 2007 | 1187 | 0.010 |
Why?
|
Gamma Rays | 1 | 2001 | 319 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10377 | 0.010 |
Why?
|
Logistic Models | 2 | 2008 | 13323 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 1996 | 9614 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1995 | 8634 | 0.010 |
Why?
|
Proportional Hazards Models | 2 | 2005 | 12558 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 13503 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1996 | 11918 | 0.010 |
Why?
|
Gamma Cameras | 1 | 1998 | 35 | 0.010 |
Why?
|
Uterine Neoplasms | 1 | 2007 | 1427 | 0.010 |
Why?
|
Antibodies, Neoplasm | 1 | 1999 | 283 | 0.010 |
Why?
|
Physicians | 1 | 1996 | 4614 | 0.010 |
Why?
|
Self-Evaluation Programs | 1 | 1997 | 29 | 0.010 |
Why?
|
Breast Self-Examination | 1 | 1997 | 33 | 0.010 |
Why?
|
Risk | 1 | 2010 | 9636 | 0.010 |
Why?
|
Perioperative Care | 1 | 2005 | 1045 | 0.010 |
Why?
|
Educational Status | 1 | 2005 | 2518 | 0.010 |
Why?
|
Pedigree | 1 | 2005 | 4544 | 0.010 |
Why?
|
Decision Trees | 1 | 1999 | 509 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2003 | 2226 | 0.010 |
Why?
|
Upstream Stimulatory Factors | 1 | 1996 | 18 | 0.010 |
Why?
|
RNA Caps | 1 | 1996 | 73 | 0.010 |
Why?
|
Attitude to Health | 1 | 2005 | 2025 | 0.010 |
Why?
|
Doxorubicin | 1 | 2003 | 2229 | 0.010 |
Why?
|
Eukaryotic Initiation Factor-4E | 1 | 1996 | 112 | 0.010 |
Why?
|
Base Sequence | 2 | 1997 | 12422 | 0.010 |
Why?
|
Paclitaxel | 1 | 2003 | 1736 | 0.010 |
Why?
|
Mass Screening | 2 | 2005 | 5451 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1997 | 1553 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9371 | 0.010 |
Why?
|
Mice | 1 | 2001 | 82017 | 0.010 |
Why?
|
Body Mass Index | 1 | 2012 | 13052 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1997 | 17626 | 0.010 |
Why?
|
Mood Disorders | 1 | 2000 | 1129 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1997 | 1992 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1996 | 1682 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 13020 | 0.010 |
Why?
|
Software | 1 | 2007 | 4453 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 1997 | 7599 | 0.010 |
Why?
|
Massachusetts | 1 | 2005 | 8902 | 0.010 |
Why?
|
Animals | 2 | 2001 | 169337 | 0.010 |
Why?
|
Alternative Splicing | 1 | 1997 | 1093 | 0.010 |
Why?
|
Models, Biological | 1 | 2008 | 9493 | 0.010 |
Why?
|
Family Health | 1 | 1996 | 1255 | 0.010 |
Why?
|
United States | 1 | 2019 | 73150 | 0.010 |
Why?
|
HeLa Cells | 1 | 1996 | 3088 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 1995 | 1748 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 1996 | 2094 | 0.010 |
Why?
|
Transfection | 1 | 1996 | 5764 | 0.000 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 10776 | 0.000 |
Why?
|
Recombinant Fusion Proteins | 1 | 1996 | 3731 | 0.000 |
Why?
|
Blotting, Western | 1 | 1995 | 5037 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1997 | 6085 | 0.000 |
Why?
|
Colorectal Neoplasms | 1 | 2007 | 6971 | 0.000 |
Why?
|
Patient Education as Topic | 1 | 1997 | 2337 | 0.000 |
Why?
|
Models, Genetic | 1 | 1996 | 3442 | 0.000 |
Why?
|
Fibroblasts | 1 | 1996 | 4177 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2007 | 26375 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 2003 | 9261 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1997 | 13423 | 0.000 |
Why?
|
Curriculum | 1 | 1997 | 3776 | 0.000 |
Why?
|
Cell Line | 1 | 1996 | 15597 | 0.000 |
Why?
|
Clinical Competence | 1 | 1997 | 4848 | 0.000 |
Why?
|
Anxiety | 1 | 1996 | 4677 | 0.000 |
Why?
|
Depression | 1 | 2000 | 8241 | 0.000 |
Why?
|
Rats | 1 | 1996 | 23835 | 0.000 |
Why?
|
Primary Health Care | 1 | 1996 | 4748 | 0.000 |
Why?
|
Transcription Factors | 1 | 1996 | 12166 | 0.000 |
Why?
|
Child | 1 | 2001 | 80891 | 0.000 |
Why?
|